Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery
Launched by UNIVERSITY OF IOWA · Jan 12, 2024
Trial Information
Current as of November 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of therapy called Acceptance and Commitment Therapy (ACT) for patients who are undergoing a surgery known as coronary artery bypass graft (CABG). CABG is often needed for people with heart disease who experience chest pain and other symptoms that don't improve with medication. The goal of this study is to see if a brief, two-session telehealth ACT intervention can help reduce anxiety and depression in patients during the days leading up to their surgery. Researchers will compare the results of those who receive ACT to a control group that gets standard care. They will also look at how this therapy affects patients' overall well-being and inflammation levels.
To participate in this trial, individuals must be admitted to the Heart and Vascular Center at the University of Iowa Hospitals and Clinics for urgent or elective CABG surgery. They should have access to a personal phone or device for video or audio calls, be able to understand the study and provide consent, and speak English. However, those with serious other health issues, active suicidal thoughts, or who have recently started certain medications may not be eligible. Participants can expect to engage in two therapy sessions from the comfort of their home and help researchers understand how to improve care for future heart surgery patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • admission to the Heart and Vascular Center at University of Iowa Hospitals and Clinics (UIHC) for urgent or elective CABG
- • access to a personal phone or device with video or audio capabilities
- • ability to provide informed consent
- • English fluency.
- Exclusion Criteria:
- • life-threatening comorbid (noncardiac) medical condition(s)
- • active suicidal ideation or intent
- • psychotropic medication use lasting less than four weeks
- • inability to provide informed consent and comply with study procedures
- • those undergoing repeat revascularization
About University Of Iowa
The University of Iowa, a leading academic and research institution, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses the expertise of its faculty and researchers to investigate cutting-edge therapies and treatments across various medical fields. Committed to ethical research practices and patient-centered care, the University of Iowa strives to contribute significantly to medical knowledge and improve health outcomes through rigorous scientific inquiry and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Iowa City, Iowa, United States
Patients applied
Trial Officials
Sara J Diesel, MA
Principal Investigator
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported